Journal article

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry J Iland, Marnie Collins, Ken Bradstock, Shane G Supple, Alberto Catalano, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Lynda J Campbell, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore Show all



BACKGROUND: Initial treatment of acute promyelocytic leukaemia traditionally involves tretinoin (all-trans retinoic acid) combined with anthracycline-based risk-adapted chemotherapy, with arsenic trioxide being the treatment of choice at relapse. To try to reduce the relapse rate, we combined arsenic trioxide with tretinoin and idarubicin in induction therapy, and used arsenic trioxide with tretinoin as consolidation therapy. METHODS: Patients with previously untreated genetically confirmed acute promyelocytic leukaemia were eligible for this study. Eligibilty also required Eastern Cooperative Oncology Group performance status 0-3, age older than 1 year, normal left ventricular ejection frac..

View full abstract